Nothing Special   »   [go: up one dir, main page]

RU2201921C2 - Производные замещенного фенила и фармацевтическая композиция на их основе - Google Patents

Производные замещенного фенила и фармацевтическая композиция на их основе Download PDF

Info

Publication number
RU2201921C2
RU2201921C2 RU97100794/04A RU97100794A RU2201921C2 RU 2201921 C2 RU2201921 C2 RU 2201921C2 RU 97100794/04 A RU97100794/04 A RU 97100794/04A RU 97100794 A RU97100794 A RU 97100794A RU 2201921 C2 RU2201921 C2 RU 2201921C2
Authority
RU
Russia
Prior art keywords
alkyl
group
methoxyphenyl
pyridine
cyclopentyloxy
Prior art date
Application number
RU97100794/04A
Other languages
English (en)
Other versions
RU97100794A (ru
Inventor
Грэхэм Джон ВАРРЕЛЛОУ
Рикки Питер Александер
Original Assignee
Селлтек Терапьютикс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9412385A external-priority patent/GB9412385D0/en
Priority claimed from GB9412492A external-priority patent/GB9412492D0/en
Application filed by Селлтек Терапьютикс Лимитед filed Critical Селлтек Терапьютикс Лимитед
Publication of RU97100794A publication Critical patent/RU97100794A/ru
Application granted granted Critical
Publication of RU2201921C2 publication Critical patent/RU2201921C2/ru

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Lock And Its Accessories (AREA)

Abstract

Изобретение относится к новым производным замещенного фенила формулы (1) или их фармацевтически приемлемым солям, гидратам или N-оксидам, где R - C1-C6-алкил, галоген - С16 алкил или С38 циклоалкил; Rа - водород, С16 алкил или галоген - С16 алкил; Z представляет группу -CHR4-CH2R5 (А) или -CR4=CHR5 (В); где R4 - водород или группа -(CH2)tAr или (СН2)tAr(Alk4)r(O)s(Alk5)t, Ar', где Ar и Ar' - фенил, необязательно замещенный заместителями, выбранными из группы, включающей С16 алкил, CF3, NO2, NH2, С16 алкилкарбониламино, С16 алкилсульфониламино и ди(С16 алкил)аминосульфониламино; Alk4 и Alk5 - С16 алкиленовые группы, необязательно замещенные галогеном или гидроксигруппой; t = 0 или целому числу 1, 2 или 3; r, s и t'' = 0 или 1, R5 представляет пиридил, необязательно замещенный фенил С16 алкилом. Соединения формулы (1) обладают ингибирующей активностью в отношении фосфодиэстеразы IV и могут оказывать терапевтическое воздействие на воспалительные заболевания. 2 с. и 6 з.п.ф-лы.

Description

Текст описания в факсимильном виде (см. графическую часть). Т Т$

Claims (8)

1. Производные замещенного фенила формулы (1)
Figure 00000003

где R представляет C16алкил, галоген-С16алкил или С38циклоалкил;
Ra представляет водород, С16алкил или галоген-С16алкил;
Z представляет группу (А) или (В)
Figure 00000004

Figure 00000005

R4 представляет водород или группу -(CH2)tAr или-(CH2)tAr(Alk4)r(O)s(Alk5)t'Ar', где Аr и Аr' каждый представляет фенил, необязательно замещенный заместителями, выбранными из группы, включающей С16алкил, СF3, NO2, NН2, С16алкилкарбониламино, С16алкилсульфониламино и ди(С16алкил)аминосульфониламино; Alk4 и Alk5 каждый представляет С16алкиленовую группу, необязательно замещенную галогеном или гидроксигруппой; t= 0 или целому числу 1, 2 или 3; r, s и t' каждый независимо представляет 0 или 1;
R5 представляет пиридил, необязательно замещенный фенилС16алкилом;
или их фармацевтически приемлемые соли, гидраты или N-оксиды.
2. Соединение по п.1, где Z представляет группу (А).
3. Соединение по пп.1 или 2, где R5 представляет необязательно замещенную 4-пиридильную группу.
4. Соединение по п.1, где Z обозначает группу (В) и R4 обозначает атом водорода.
5. Соединение по п.1, которое представляет собой:
(Е)- и (Z) - изомеры 4-[2-(3-циклопентилокси-4-метоксифенил)этенил-3-(фенилэтил)пиридин);
(±)-4-[2-(3-циклопентилокси-4-метоксифенил)этил-3-фенилэтил)пиридин;
(±)-4-{ 2-[4-(4-аминофенилокси)фенил] -2(3-циклопентил-окси-4-метоксифенил)этил}пиридин;
(±)-4-{ 2-[4-(4-ацетамидофенилокси)фенил] -2-(3-цикло-пентилокси-4-метоксифенил)этил}пиридин;
(±)-4-{ 2-(3-циклопентилокси-4-метоксифенил)-2-[4-(4-N',N'-диметиламиносульфониламинофенил)фенилокси]этил}пиридин;
(±)-4-{ 2-(3-циклопентилокси-4-метоксифенил)-2-[4-(4-метилсульфониламинофенил)фенилокси]этил}пиридин;
(±)-4-[2-(3-циклопентилокси-4-метоксифенил)-2-(4'-метил-4-бифенил)этил] пиридин;
(±)-N-{ 3-[1-(3-циклопентилокси-4-метоксифенил)-2-(4-пиридил)этил]фенилметил}-N'-фенилмочевина;
или его индивидуальные изомеры, разделенные энантиомеры, соли, гидраты или N-оксиды.
6. Соединение по п.1, которое представляет собой (±)-4-{2-(3-циклопентилокси-4-метоксифенил)-2-[4-(4-трифторметилфенил)фенилэтил] } пиридин или его индивидуальные изомеры, разделенные энантиомеры, соли, гидраты или N-оксиды.
7. Соединение по п.1, которое представляет собой (±)-4-[2-(4-бензилоксифенил)-2-(3-циклопентилокси-4-метоксифенил)этил] пиридин; (±)-4-{ 2-(3-циклопентилокси-4-метоксифенил)-2-[4-(4-нитрофенилокси)фенил] этил} пиридин или его индивидуальные изомеры, разделенные энантиомеры, соли, гидраты или N-оксиды.
8. Фармацевтическая композиция, обладающая ингибирующей активностью в отношении фосфодиэстеразы IV, включающая соединение формулы (1) по любому из пп. 1-7 или его фармацевтически приемлемые соли, гидраты или N-оксиды и один или более фармацевтически приемлемый носитель, наполнитель или разбавитель.
Приоритет по пунктам:
21.06.1994 по п.7;
22.06.1994 по п.6;
21.06.1995 по пп.1-5 и 8.
RU97100794/04A 1994-06-21 1995-06-21 Производные замещенного фенила и фармацевтическая композиция на их основе RU2201921C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9412385.8 1994-06-21
GB9412385A GB9412385D0 (en) 1994-06-21 1994-06-21 Chemical compounds
GB9412492.2 1994-06-22
GB9412492A GB9412492D0 (en) 1994-06-22 1994-06-22 Chemical compounds

Publications (2)

Publication Number Publication Date
RU97100794A RU97100794A (ru) 1999-02-20
RU2201921C2 true RU2201921C2 (ru) 2003-04-10

Family

ID=26305090

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97100794/04A RU2201921C2 (ru) 1994-06-21 1995-06-21 Производные замещенного фенила и фармацевтическая композиция на их основе

Country Status (18)

Country Link
US (2) US5786354A (ru)
EP (1) EP0770065B1 (ru)
JP (1) JP3856465B2 (ru)
CN (1) CN1304372C (ru)
AT (1) ATE263153T1 (ru)
AU (1) AU707472B2 (ru)
CZ (1) CZ293311B6 (ru)
DE (1) DE69532808T2 (ru)
DK (1) DK0770065T3 (ru)
ES (1) ES2218548T3 (ru)
FI (1) FI115302B (ru)
HU (1) HUT76803A (ru)
NO (1) NO312672B1 (ru)
NZ (1) NZ288294A (ru)
PT (1) PT770065E (ru)
RU (1) RU2201921C2 (ru)
SK (1) SK282661B6 (ru)
WO (1) WO1995035281A1 (ru)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
EP0738268B1 (en) * 1993-12-22 2004-03-03 Celltech R&D Limited Trisubstituted phenyl derivatives, processes for their preparation and their use as phosphodiesterase (type iv) inhibitors
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CA2238875C (en) * 1995-12-15 2003-09-16 Merck Frosst Canada Inc. Tri-aryl ethane derivatives as pde iv inhibitors
US5710170A (en) * 1995-12-15 1998-01-20 Merck Frosst Canada, Inc. Tri-aryl ethane derivatives as PDE IV inhibitors
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
DE19605766A1 (de) * 1996-02-16 1997-08-21 Basf Ag Substituierte 2-Phenylpyridine
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
JP2001507349A (ja) 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式2−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
US6180650B1 (en) * 1999-04-23 2001-01-30 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
MXPA02001830A (es) 1999-08-21 2002-08-12 Byk Gulden Lomberg Chem Fab Combinacion sinergica de inhibidores de pde y agonista de beta 2 adrenoceptor.
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
US6410563B1 (en) 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
MY123585A (en) * 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
US6639077B2 (en) 2000-03-23 2003-10-28 Merck Frosst Canada & Co. Tri-aryl-substituted-ethane PDE4 inhibitors
JP2003534328A (ja) 2000-05-25 2003-11-18 メルク フロスト カナダ アンド カンパニー フルオロアルコキシ置換ベンズアミドジクロロピリジニルn−オキシドpde4阻害剤
US6740666B2 (en) 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US6699890B2 (en) 2000-12-22 2004-03-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
DE10064997A1 (de) 2000-12-23 2002-06-27 Merck Patent Gmbh Benzoylpyridazine
US7205320B2 (en) * 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7153871B2 (en) * 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
ATE303384T1 (de) 2001-05-24 2005-09-15 Merck Frosst Canada Inc 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
AU2002312933B2 (en) * 2001-05-29 2007-12-06 Schering Ag CDK inhibiting pyrimidines, production thereof and their use as medicaments
JO2311B1 (en) 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
DE10150517A1 (de) * 2001-10-12 2003-04-17 Merck Patent Gmbh Verwendung von Phosphodiesterase IV-Inhibitoren
CA2492907A1 (en) 2002-07-19 2004-01-29 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
BR0313000A (pt) 2002-07-19 2005-07-12 Memory Pharm Corp Compostos, composição farmacêutica e método para efetuar a inibição da enzima pde4, realçar a cognição e/ou tratar a psicose em um paciente
RU2356893C2 (ru) * 2002-11-19 2009-05-27 Мемори Фармасьютиклз Корпорейшн Ингибиторы фосфодиэстеразы 4
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1624893A2 (en) 2003-04-01 2006-02-15 Applied Research Systems ARS Holding N.V. Inhibitors of phosphodiesterases in infertility
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
AU2005295788A1 (en) * 2004-10-13 2006-04-27 Wyeth N-benzenesulfonyl substituted anilino-pyrimidine analogs
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
ATE496029T1 (de) * 2006-07-14 2011-02-15 Chiesi Farma Spa Derivate von 1-phenyl-2-pyridinylalkylenalkohole als phosphodiesteraseinhibitoren
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2998314B1 (en) 2007-06-04 2020-01-22 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2022783A1 (en) * 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2070913A1 (en) 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester derivatives as phosphodiesterase inhibitors
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US20100029689A1 (en) * 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2226323A1 (en) 2009-02-27 2010-09-08 Almirall, S.A. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
EP2380890A1 (en) 2010-04-23 2011-10-26 Almirall, S.A. New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP3366698A1 (en) 2011-03-01 2018-08-29 Synergy Pharmaceuticals Inc. Guanylate cyclase c agonists
MX2013013557A (es) 2011-06-06 2013-12-16 Chiesi Farma Spa Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de fosfodiesterasa.
WO2013045280A1 (en) 2011-09-26 2013-04-04 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
RU2617401C2 (ru) 2011-10-21 2017-04-25 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстеразы
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
RU2637945C2 (ru) 2012-06-04 2017-12-08 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Производные 1-фенил-2-пиридинил-алкиловых спиртов в качестве ингибиторов фосфодиэстеразы
KR102192739B1 (ko) 2012-12-05 2020-12-18 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제로서 1-페닐-2-피리디닐 알킬 알코올의 유도체
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
BR112016002789A2 (pt) 2013-08-09 2017-11-21 Ardelyx Inc compostos e métodos para inibir transporte de fosfato
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1285932A (fr) * 1960-12-26 1962-03-02 Nord Aviation Charge creuse
US3947467A (en) * 1973-08-02 1976-03-30 Eli Lilly And Company 3-(5-Nitro-2-imidazolyl) pyrazoles
FR2257272B1 (ru) * 1974-01-15 1978-08-25 Pharmascience Labo
DE2413935A1 (de) * 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
DE2541855A1 (de) * 1975-09-18 1977-03-31 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone ii
FR2313422A2 (fr) * 1975-06-02 1976-12-31 Labaz Nouveaux stabilisants des polymeres et copolymeres du chlorure de vinyle
SU888821A3 (ru) * 1976-12-03 1981-12-07 Шеринг Аг (Инофирма) Способ получени 5-(замещенный фенил)-оксазолидинонов или их серусодержащих аналогов
ATE798T1 (de) * 1978-06-15 1982-04-15 Imperial Chemical Industries Plc Entzuendungshemmende 1-phe nyl-2-aminoaethanol-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen zur oertlichen anwendung.
EP0112707B1 (en) * 1982-12-23 1987-11-04 Smith Kline & French Laboratories Limited Aminopyrimidinone derivatives as histamine h1-antagonists
IT1161221B (it) * 1983-04-21 1987-03-18 Ripharm Srl Composto per il trattamento della psoriasi
ATE60591T1 (de) * 1984-06-25 1991-02-15 Ciba Geigy Ag Pyrimidinderivate wirksam als schaedlingsbekaempfungsmittel.
EP0233461B2 (en) * 1986-01-13 2002-05-29 American Cyanamid Company 4,5,6-Substituted-2-pyrimidinamines
US4876252A (en) * 1986-01-13 1989-10-24 American Cyanamid Company 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines
US4788195A (en) * 1986-01-13 1988-11-29 American Cyanamid Company 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines
HU215433B (hu) * 1986-04-29 2000-05-28 Pfizer Inc. Eljárás új 2-oxo-5-fenil-pirimidin-származékok előállítására
US5128358A (en) * 1988-01-19 1992-07-07 Pfizer Inc. Aryl substituted nitrogen heterocyclic antidepressants
US4921862A (en) * 1986-05-29 1990-05-01 Syntex (U.S.A.) Inc. Carbostyril derivatives as combined thromboxane synthetase and cyclic-amp phosphodiesterase inhibitors
US4792561A (en) * 1986-05-29 1988-12-20 Syntex (U.S.A.) Inc. Carbostyril derivatives as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors
CN1030415A (zh) * 1987-02-20 1989-01-18 山之内制药株式会社 饱和的杂环碳酰胺衍生物和它的制备方法
US4971959A (en) * 1987-04-14 1990-11-20 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
US5274002A (en) * 1987-04-14 1993-12-28 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
DE3882821D1 (de) * 1987-06-11 1993-09-09 Ciba Geigy Ag Mikrobizide.
US4966622A (en) * 1988-04-12 1990-10-30 Ciba-Geigy Corporation N-phenyl-N-pyrimidin-2-ylureas
US4897396A (en) * 1988-06-03 1990-01-30 Ciba-Geigy Corporation 2-phenylamino pyrimidine derivatives and their uses as microbicides
DK0469013T3 (da) * 1989-04-17 1995-10-02 Byk Gulden Lomberg Chem Fab Hidtil ukendte arylpyridaziner, fremstilling deraf, anvendelse deraf og lægemidler indeholdende disse
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
JPH075572B2 (ja) * 1989-08-18 1995-01-25 積水化学工業株式会社 2―[2―(2―ヒドロキシフェニル)ビニルピラジンおよびその製造法
JPH0377923A (ja) * 1989-08-18 1991-04-03 Sekisui Chem Co Ltd 有機非線形光学材料
DE4003919A1 (de) * 1990-02-09 1991-08-14 Basf Ag Heteroarylalkene, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung
GB9007762D0 (en) * 1990-04-05 1990-06-06 Beecham Group Plc Novel compounds
WO1991016892A1 (en) * 1990-04-27 1991-11-14 Rorer International (Holdings), Inc. Styryl compounds which inhibit egf receptor protein tyrosine kinase
WO1992000968A1 (en) * 1990-07-10 1992-01-23 Smithkline Beecham Corporation Oxamides
US5124455A (en) * 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
EP0550576A1 (en) * 1990-09-28 1993-07-14 Smith Kline & French Laboratories Limited Phenylpyridinol derivatives as medicaments
DE59109027D1 (en) * 1990-10-16 1998-08-13 Byk Gulden Lomberg Chem Fab Arylpyridazinone
CA2095429A1 (en) * 1990-11-06 1992-05-07 Paul E. Bender Imidazolidinone compounds
SE470395B (sv) * 1990-12-05 1994-02-14 Erik Lindgren Produktide Ab Ryggstödjande anordning
GB9027055D0 (en) * 1990-12-13 1991-02-06 Sandoz Ltd Organic compounds
US5698711A (en) * 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
IE71647B1 (en) * 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
WO1992019602A1 (de) * 1991-04-26 1992-11-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue pyridazine
US5191084A (en) * 1991-05-01 1993-03-02 American Home Products Corporation Phenyl pyrazolidinones as bronchodilators and anti-inflammatory agents
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
EP0540165A1 (en) * 1991-10-03 1993-05-05 Zeneca Limited Alkanoic acid derivatives
CA2080554A1 (en) * 1991-10-15 1993-04-16 Mitsubishi Chemical Corporation Styrene derivatives
DE4136921A1 (de) * 1991-11-11 1993-05-13 Knoll Ag Verfahren zur trennung von 5-methyl-tetrahydrofolsaeure
US5326898A (en) * 1992-02-11 1994-07-05 Allergan, Inc. Substituted phenylethenyl compounds having retinoid-like biological activity
EP0633775B1 (en) * 1992-04-02 2000-05-31 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and for inhibiting production of tumor necrosis factor
TW225528B (ru) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB9212673D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
GB9212693D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
WO1994002465A1 (en) * 1992-07-28 1994-02-03 Rhone-Poulenc Rorer Limited INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
JP3100984B2 (ja) * 1992-12-02 2000-10-23 ファイザー・インク. 選択的pde▲下i▼▲下v▼阻害物質としてのカテコールジエーテル類
KR100190730B1 (ko) * 1992-12-17 1999-06-01 디. 제이. 우드, 스피겔 알렌 제이 부신피질 호르몬 유리인자(crf) 길항물질로서 치환된 피라졸
US5622977A (en) * 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
TW263495B (ru) * 1992-12-23 1995-11-21 Celltech Ltd
GB9226830D0 (en) * 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9315595D0 (en) * 1993-07-28 1993-09-08 Res Inst Medicine Chem New compounds
EP0672042B1 (en) * 1993-10-01 2006-05-03 Novartis AG Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
HU228172B1 (en) * 1993-10-01 2013-01-28 Novartis Ag Pharmacologically active pyridine derivatives and their preparation
WO1995009847A1 (en) * 1993-10-01 1995-04-13 Ciba-Geigy Ag Pyrimidineamine derivatives and processes for the preparation thereof
KR0182324B1 (ko) * 1993-11-26 1999-05-01 알렌 제이. 스피겔 항염증제로서의 이속사졸린 화합물
GB9326173D0 (en) * 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
GB9326600D0 (en) * 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
EP0738268B1 (en) * 1993-12-22 2004-03-03 Celltech R&D Limited Trisubstituted phenyl derivatives, processes for their preparation and their use as phosphodiesterase (type iv) inhibitors
US5691376A (en) * 1994-02-17 1997-11-25 American Home Products Corporation Substituted biphenyl derivatives
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
CN1149870A (zh) * 1994-06-06 1997-05-14 辉瑞大药厂 具有促皮质激素释放因子拮抗剂活性的取代的吡唑
US6245774B1 (en) * 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412571D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412573D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
JPH09509851A (ja) * 1994-12-23 1997-10-07 セルテック セラピューティックス リミテッド ヒトホスホジエステラーゼ型ivc、並びにその生産および使用
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
ES2180798T3 (es) * 1995-10-02 2003-02-16 Hoffmann La Roche Derivados de pirimidina como antagonistas del receptor de 5ht2c.
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds

Also Published As

Publication number Publication date
CZ373096A3 (en) 1997-08-13
US5786354A (en) 1998-07-28
FI965126A (fi) 1996-12-19
CN1304372C (zh) 2007-03-14
NO965524L (no) 1996-12-20
FI115302B (fi) 2005-04-15
HU9603578D0 (en) 1997-02-28
PT770065E (pt) 2004-08-31
DE69532808T2 (de) 2005-01-13
NO312672B1 (no) 2002-06-17
FI965126A0 (fi) 1996-12-19
SK282661B6 (sk) 2002-11-06
EP0770065A1 (en) 1997-05-02
WO1995035281A1 (en) 1995-12-28
DK0770065T3 (da) 2004-07-19
NO965524D0 (no) 1996-12-20
DE69532808D1 (de) 2004-05-06
JP3856465B2 (ja) 2006-12-13
HUT76803A (en) 1997-11-28
CZ293311B6 (cs) 2004-03-17
SK163096A3 (en) 1997-10-08
JPH10503173A (ja) 1998-03-24
AU707472B2 (en) 1999-07-08
NZ288294A (en) 1999-01-28
US6077854A (en) 2000-06-20
AU2746195A (en) 1996-01-15
EP0770065B1 (en) 2004-03-31
CN1151732A (zh) 1997-06-11
ES2218548T3 (es) 2004-11-16
ATE263153T1 (de) 2004-04-15

Similar Documents

Publication Publication Date Title
RU2201921C2 (ru) Производные замещенного фенила и фармацевтическая композиция на их основе
RU2221790C2 (ru) Новые производные пиридазина и лекарственные средства, содержащие их в качестве эффективных ингредиентов
RU2221795C2 (ru) Имидазолил-циклические ацетали, промежуточные соединения, фармацевтическая композиция и способ лечения
RU2214400C2 (ru) Производные 1-[(1-замещенного-4-пиперидинил)метил]-4-пиперидина, способы их получения, фармацевтическая композиция на их основе и промежуточные вещества
RU2403247C2 (ru) Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения
US6576646B1 (en) Methods for treating cognitive impairments caused by traumatic brain injuries
RU2002122095A (ru) Новое пипиридиновое соединение и его фармацевтическая композиция
RU2003129502A (ru) Соединение, фармацевтическая композиция, применение, способ предупреждения или лечения заболеваний
RU99104152A (ru) Циклические аминопроизводные
US20040242634A1 (en) Methods for treating prion diseases
RU2001118466A (ru) Арил- и гетероциклилзамещенные пиримидиновые производные в качестве антикоагулянтов
RU2005113168A (ru) Производные 2-пиридона в качестве ингибитора нейтрофильной эластазы
KR970015578A (ko) 아릴알킬 디아진온
RU97105769A (ru) Гетероциклическое производное и лекарственное средство
RU2007101275A (ru) Новые цис-имидазолины
RU97114306A (ru) Фенилзамещенные гуанидины алкенилкарбоновой кислоты, способ их получения, их применение в качестве лекарственного или диагностического средства, а также содержащее их лекарственное средство
IL205501A (en) Preparation of preparations for the treatment of arthritis
JPH06500078A (ja) Tnf抑制剤
RU2000100935A (ru) Производные ароил-пиперазина, их получение и их использование в качестве антагонистов тахикинина
CA2475619A1 (en) Piperidine derivatives
RU2009148507A (ru) Производное тетрагидроизохинолин-1-она или его соль
RU99101081A (ru) Режим введения ингибиторов н+, к+-атфазы
RU97103983A (ru) Лекарственные композиции и производные триазина
MX2007012070A (es) Tratamiento de la epilepsia con ligandos del receptor h3 de histamina, tipo alquilaminas no imidazol.
RU2005131014A (ru) Азотосодержащие гетероциклические производные, содержащие 2, 6-дизамещенный стирил

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20070622